Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Anatara Lifesciences Ltd (ASX:ANR) Achieves a Major US FDA Milestone in the Registration of Detach(R) with Approval of the Human Food Safety Dossier
Anatara Lifesciences (ASX:ANR) has achieved a significant milestone in the United States of America after receiving a "complete" letter from the US Food and Drug Administration for the Technical Section of its Human Food Safety submission. The HFS is a major component of a New Animal Drug Application which is currently underway and is necessary for enabling the marketing of Detach(R) in the US.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.
At the Australasian Pig Science Association Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (ASX:ANR) Detach(R) product to in-feed Zinc oxide in reducing diarrhoea and antibiotic treatments in post-weaning piglets.
Anatara Lifesciences Ltd (ASX:ANR) provides the Chairman's address to shareholders.
Anatara Lifesciences Ltd (ASX:ANR) Dr Tracey Mynott Presents at TRI Science Business Inspiration Series
Anatara Lifesciences (ASX:ANR) CSO, Dr Tracey Mynott, was recently invited to present at the Translational Research Institute's Science Business Inspiration Series. The series was launched with Session 1 "The whole journey: from idea to reality".
Anatara Lifesciences (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Annual Report 2017 Update.
Anatara Lifesciences Limited (ASX:ANR) has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre in 2015.
Anatara Lifesciences Ltd (ASX:ANR) and Zoetis to Negotiate Terms of International Detach(R) Commercial Agreement
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that global animal health company, Zoetis Inc. has exercised its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R), with terms to be agreed.